No Serious HRQOL Decline With FOLFOXIRI/Bevacizumab

Share this content:
HRQOL decreases of note were not reported with FOLFOXIRI/bevacizumab therapy for metastatic colorectal cancer.
HRQOL decreases of note were not reported with FOLFOXIRI/bevacizumab therapy for metastatic colorectal cancer.
The following article features coverage from the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois. Click here to read more of Oncology Nurse Advisor's conference coverage. 

CHICAGO—Researchers who compared FOLFOXIRI/bevacizumab with FOLFOX/bevacizumab in the treatment of metastatic colorectal cancer found no remarkable detriment in health-related quality of life (HRQOL) with either regimen, according to a poster presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

The better efficacy of FOLFOXIRI/bevacizumab compared with FOLFOX/bevacizumab, however, is associated with a decrease mainly in gastrointestinal QOL scores, the investigators concluded.

Julia Quidde, MD, of the University Hospital Hamburg-Eppendorf (UKE) in Hamburg, Germany, and colleagues noted that FOLFOXIRI/bevacizumab is a highly efficacious first-line therapy for metastatic colorectal cancer, but nothing is known about the impact of this regimen on HRQOL.

Dr Quidde's group randomly assigned 250 patients to receive FOLFOX/bevacizumab (arm A) or FOLFOXIRI/bevacizumab (arm B). Investigators used European Organisation for Research and Treatment of Cancer (EORTC) questionnaires (QLQ-C30, QLQ-CR29 and QLQ-CIPN20) to assess HRQOL at baseline, every 8 weeks during induction treatment (6 months), and every 12 weeks during maintenance treatment. For the HRQOL analysis, 237 patients were eligible (118 in arm A and 119 in arm B).

The compliance rate with the HRQOL questionnaires was 95.4% at baseline, 72.6% at week 8, 59.5% at week 16, 43.5% at week 24. The treatment arms had similar mean global QOL scores, but mean scores for nausea/vomiting and diarrhea favored arm A significantly or borderline significantly during induction. At week 8, scores of nausea/vomiting, appetite loss, financial problems, and physical functioning at the end of treatment were significantly better for arm A than arm B.

The investigators observed no significant differences in the remaining EORTC scores. The rates of deterioration and improvement from baseline to week 8 of at least 10 points in the EORTC scores were similar. For example, the deterioration rate according to global QOL score was 21.5% and 26.5% for arm A and B, respectively (P

=.461).

Read more of Oncology Nurse Advisor's coverage of the 2017 American Society of Clinical Oncology Annual Meeting by visiting the conference page.

Reference

1. Quidde J, Schmoll HJ, Garlipp B, et al. Impact of FOLFOXIRI and bevacizumab (bev) compared to FOLFOX and bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRC): analysis of the CHARTA-AIO 0209 trial. Poster presentation at: 2017 American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs